Ultragenyx Pharmaceutical (NASDAQ:RARE) Earns “Neutral” Rating from Wedbush

Ultragenyx Pharmaceutical (NASDAQ:RARE)‘s stock had its “neutral” rating reiterated by equities researchers at Wedbush in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $48.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $46.00. Wedbush’s target price points to a potential upside of 19.94% from the company’s previous close.

Several other brokerages also recently commented on RARE. HC Wainwright reaffirmed a “buy” rating and issued a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, December 24th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $77.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $116.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. Wells Fargo & Company lifted their price target on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an “overweight” rating in a research report on Friday, December 20th. Finally, TD Cowen lifted their price target on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $92.29.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE stock opened at $40.02 on Monday. The stock’s 50 day simple moving average is $45.69 and its 200 day simple moving average is $49.64. Ultragenyx Pharmaceutical has a twelve month low of $37.02 and a twelve month high of $60.37. The company has a market capitalization of $3.70 billion, a price-to-earnings ratio of -6.19 and a beta of 0.58.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The business had revenue of $139.49 million for the quarter, compared to the consensus estimate of $135.28 million. During the same period last year, the business earned ($2.23) EPS. The firm’s revenue was up 42.3% compared to the same quarter last year. On average, analysts forecast that Ultragenyx Pharmaceutical will post -6.2 EPS for the current fiscal year.

Insider Transactions at Ultragenyx Pharmaceutical

In related news, CEO Emil D. Kakkis sold 8,273 shares of the business’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $50.00, for a total value of $413,650.00. Following the sale, the chief executive officer now owns 2,195,712 shares of the company’s stock, valued at $109,785,600. The trade was a 0.38 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.80% of the stock is owned by insiders.

Institutional Trading of Ultragenyx Pharmaceutical

Several institutional investors have recently bought and sold shares of RARE. True Wealth Design LLC acquired a new position in Ultragenyx Pharmaceutical in the third quarter worth $43,000. Values First Advisors Inc. acquired a new position in Ultragenyx Pharmaceutical in the third quarter worth $56,000. Wilmington Savings Fund Society FSB acquired a new position in Ultragenyx Pharmaceutical in the third quarter worth $83,000. Nomura Asset Management Co. Ltd. acquired a new position in Ultragenyx Pharmaceutical in the third quarter worth $93,000. Finally, Capital Performance Advisors LLP acquired a new position in Ultragenyx Pharmaceutical in the third quarter worth $107,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.